Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Natalizumab - Biogen/Perrigo

Drug Profile

Natalizumab - Biogen/Perrigo

Alternative Names: AN 10022; AN 100226; Antegren; Anti-alpha4 integrin monoclonal antibody; BG-00002; BG-0002; BG-0002-E; Tysabri

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Corporation
  • Developer Biogen; Biogen Idec; Elan Corporation; Perrigo
  • Class Antineoplastics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Multiple sclerosis
  • Phase II Epilepsy; Graft-versus-host disease; Stroke
  • Discontinued Multiple myeloma; Rheumatoid arthritis

Most Recent Events

  • 13 Sep 2019 Updated efficacy data from a phase IV Tysabri Observational Program (TOP) released by Biogen
  • 13 Sep 2019 Biogen completes enrolment in a phase IIIb NOVA trial for Multiple Sclerosis in USA, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain and in the UK (NCT03689972)
  • 12 Mar 2019 Biogen enters into a share purchase agreement with Fujifilm Corporation for Biogen’s biologics manufacturing operations in Hillerød, Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top